Compounded vs branded GLP-1: what's the difference?

Branded GLP-1s (Wegovy, Zepbound, Ozempic, Mounjaro) are FDA-approved, made to a consistent dose, and backed by the clinical trials. Compounded versions are mixed by pharmacies, are not FDA-approved for safety or effectiveness, and are now tightly restricted after the drug shortages that made them common resolved. They are not the same product, and outside a narrow, patient-specific case, they are no longer a legitimate substitute.

Key takeaways

• Branded GLP-1s are FDA-approved; compounded versions are not reviewed by the FDA for safety, quality, or effectiveness.
• Compounding surged only because of shortages — those shortages resolved (tirzepatide October 2024, semaglutide February 2025).
• With the shortages over, the legal pathways for mass compounding have closed; the FDA proposed in April 2026 to remove these drugs from the 503B bulk-compounding list.
• The FDA has logged hundreds of adverse-event reports tied to compounded GLP-1s, many from dosing errors.
• A narrow, legitimate role remains: patient-specific compounding at a 503A pharmacy when a clinical need can't be met by the commercial product.

Compounded vs branded at a glance

What "compounded" actually means

Compounding is when a licensed pharmacy mixes a medication to order rather than dispensing a manufacturer's finished product. Two kinds of facility do it: 503A pharmacies compound for an individual patient against a prescription, and 503B outsourcing facilities make larger batches. Compounded drugs are legal in specific situations, but they are not FDA-approved — the agency does not review them for safety, effectiveness, or quality before they reach patients.

Why compounded GLP-1s became common — and why that changed

They filled a gap. Federal law allows compounding of a drug that is on the FDA shortage list, and semaglutide and tirzepatide were both in shortage as demand exploded. That opened the door to widespread compounded versions, often marketed on price.

The door is closing because the shortages ended: the FDA declared the tirzepatide shortage resolved in October 2024 and semaglutide in February 2025. Once a drug is off the shortage list, the shortage-based justification for compounding it goes away, and the FDA set enforcement deadlines through 2025 to wind it down. In April 2026 the agency went further, proposing to remove semaglutide, tirzepatide, and liraglutide from the 503B bulk-compounding list, which would close the last large-scale pathway.

Is compounded semaglutide safe?

It carries risks the branded product does not. Because compounded versions are not FDA-reviewed, potency and sterility can vary between pharmacies. The FDA has received hundreds of adverse-event reports tied to compounded semaglutide and tirzepatide, many involving dosing errors when patients draw doses from multi-dose vials. There have also been cautions about compounders using different salt forms (such as semaglutide sodium or acetate) that are not the same as the approved medication and are not established as safe or effective. None of this means every compounded dose is dangerous, but it does mean you are taking on uncertainty the branded product removes.

When is compounding actually appropriate?

There is a real, narrow case. A 503A pharmacy can compound for a specific patient when a clinical need cannot be met by the commercial product — for example, a documented allergy to an inactive ingredient in the branded pen. That is a clinician-driven decision for an individual, not a discount channel for everyone. If the only reason a program is steering you to compounded is price, treat that as a flag, not a feature.

How OPTMZ handles it

At OPTMZ, branded GLP-1s are the public offering. A compounded alternative is only ever discussed privately with your clinician when it is clinically appropriate for your specific situation — never advertised, never a hero offer, and never priced as the reason to choose us. We are independent of any pharmaceutical manufacturer, and treatment follows a clinician evaluation and labs. See the Weight loss program, and for the broader picture read GLP-1 without the hype.

OPTMZ's branded GLP-1 offering is Zepbound® (tirzepatide), via LillyDirect — see the Weight program.

Educational content, medically reviewed. Not a substitute for individual medical care; treatment decisions require a clinician evaluation.

Medications are issued only when clinically appropriate after provider evaluation. OPTMZ Health connects patients with independent licensed providers and does not itself practice medicine or dispense medication.

Sources

• U.S. FDA. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. fda.gov
• U.S. FDA. Declaratory Order: Resolution of Shortages of Semaglutide Injection. fda.gov
• SURMOUNT-5: Tirzepatide versus Semaglutide for the Treatment of Obesity. New England Journal of Medicine, 2025. nejm.org